MC-Val-Cit-PAB-Auristatin E

• CAT Number: I018052
• CAS Number: 2055896-77-8
• Molecular Formula: C68H108N11O13
• Molecular Weight: 1287.65
• Purity: ≥95%
• Synonyms: [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-dimethylazanium
• InChI: InChI=1S/C68H107N11O13/c1-16-44(8)59(52(91-14)39-56(83)77-38-24-28-51(77)62(92-15)45(9)63(85)71-46(10)61(84)48-25-19-17-20-26-48)76(11)67(89)58(42(4)5)75-66(88)60(43(6)7)79(12,13)40-47-30-32-49(33-31-47)72-64(86)50(27-23-36-70-68(69)90)73-65(87)57(41(2)3)74-53(80)29-21-18-22-37-78-54(81)34-35-55(78)82/h17,19-20,25-26,30-35,41-46,50-52,57-62,84H,16,18,21-24,27-29,36-40H2,1-15H3,(H7-,69,70,71,72,73,74,75,80,85,86,87,88,90)/p+1/t44-,45+,46+,50-,51-,52+,57-,58-,59-,60-,61+,62+/m0/s1
• InChIKey: ULBSEZSVDXRNQN-UIMDRQLBSA-O
• SMILES: CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)[N+](C)(C)CC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN4C(=O)C=CC4=O

MC-Val-Cit-PAB-Auristatin E（Cat No.:I018052）is a potent antibody–drug conjugate (ADC) linker-toxin system widely used in cancer research. The construct employs a dipeptide linker (valine–citrulline) with a para-aminobenzyloxycarbonyl (PAB) spacer, enabling controlled drug release upon cleavage by cathepsin B in lysosomes. This design ensures targeted intracellular delivery, minimizing systemic toxicity. Auristatin E, a synthetic analog of dolastatin 10, disrupts microtubule dynamics and induces apoptosis in rapidly dividing tumor cells, making it highly effective in evaluating targeted therapies and advancing ADC development for oncology research.